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 Abstract 
The field of epigenetics now occupy a leading position in the studies relating to diverse 
processes such as transcriptional regulation, chromatin structure, genome integrity, and 
tumorigenesis. Recent works have demonstrated  how DNA methylation and chromatin structure 
are linked at the molecular level and how alterations in  methylation play a role in tumorigenesis 
and genetic diseases. The cellular methylation machinery, known as the DNA 
methyltransferases, plays a major role in mammalian development in terms of the types of 
proteins they are known to interact with. Recent informations explain how cellular DNA 
methylation patterns may be established during development and maintained in somatic cells. 
Emerging evidence indicates that various chromatin states such as histone modifications 
(acetylation and methylation) and nucleosome positioning (modulated by ATP-dependent 
chromatin remodeling machines) determine DNA methylation patterning. Additionally, various 
regulatory factors interacting with the DNA methyltransferases and direct them to specific DNA 
sequences, regulate their enzymatic activity, and allow their use as transcriptional repressors. 
Connections between DNA methylation and chromatin structure and the DNA methyltransferase 
associated proteins, reveal that many, if not all, epigenetic modifications of the genome are 
directly connected. Such studies should also yield new insights into treating diseases involving 
aberrant DNA methylation like cancer. 
 
 
 
 
 
 
 
 
 
Introduction 
Cancer is a process driven by the accumulation of abnormalities in gene function. While many of 
these changes are genetic, epigenetically mediated changes in gene expression are being 
increasingly appreciated. This latter process involves two components of heritable, but 
reversible, modulation of gene promoter function that are closely tied to one another - formation 
of chromatin which modulates transcription and establishing patterns of DNA methylation 
(Michael R Rountree, et al ,2001).Epigenetic  alterations are universally present in human cancer 
and result in heritable changes in gene expression and chromatin structure over many cell 
generations without changes in DNA sequence, leading to functional consequences equivalent to 
those induced by genetic alteration (Carla Sawan , et al , 2008).Changes in DNA methylation 
pattern plays an important role in the development of cancer. The correct pattern of genomic 
methylation is essential for healthy cells and organs. If methylation patterns are not properly 
established or maintained, disorders as diverse as mental retardation, immune deficiency, and 
sporadic or inherited cancers may follow. 
          
          DNA methylation involves the covalent addition of a methyl group to cytosine within the 
CpG dinucleotide to form methlcytosine  has profound effects on the mammalian genome. This 
reaction is catalyzed by DNA methyltransferase in the context of the sequence 5’-CG-3’, which is 
also referred to as a CpG dinucleotide. It is the most common eukaryotic DNA modification 
and is one of the many epigenetic (alteration in gene expression without a change in nucleotide 
sequence) phenomena ( Rakesh Singal and Gordon D. Ginder , 2011).The effects of DNA 
methylation include transcriptional repression via inhibition of transcription factor binding or the 
recruitment of methyl binding protein and their associated chromatin remodeling factors , X- 
chromosome inactivation , imprinting and the suppression of parasitic DNA sequences. DNA 
methylation is also important for the proper embryonic development of the organism (Keith D. 
Robertson and Peter A. Jones , 2000). These diverse processes nevertheless appear to share a 
common characteristic, that is, they all exert a stabilizing effect which promotes genomic 
integrity and ensures proper temporal and spatial gene expression during development. 
 
Genomic DNA methylation patterns are not randomly distributed. Rather, discrete regions, 
including most repetitive and parasitic DNA, are hypermethylated, while other regions, such as 
CpG- rich regions often associated with the regulatory regions of genes (CpG islands), are 
hypomethylated (Yoder et al., 1997). Furthermore, DNA methylation patterns change 
dramatically during embryonic development. Genome wide demethylation after fertilization 
is followed by waves of de novo methylation upon embryo implantation. Not all sequences in the 
genome, however, are demethylated upon fertilization and not all sequences become de novo 
methylated after implantation. These exceptions further emphasize the regional specificity of 
genomic DNA methylation patterning (Reik et al., 2001). Evidence of the great importance of 
these methylation patterns can be acquired  by examining the effects of disrupting them in vivo. 
Naturally occurring mutations in genes involved in controlling DNA methylation patterns, 
including one of the DNA methyltransferases, result in ICF, Rett, ATRX and fragile X 
syndromes (Robertson and Wolffe, 2000). Disruption of normal DNA methylation patterns is 
one of the most common features of transformed cells and a number of studies have revealed that 
methylation changes are early events in the tumorigenesis process and contribute directly to 
transformation. In tumor cells the normal regulation of the DNA methylation machinery is 
severely disrupted, such that the regional specificity of methylation patterns begins to be 
reversed, resulting in de novo methylation of CpG islands and hypomethylation of repetitive 
DNA (Baylin et al., 2001; Jones and Laird, 1999; Robertson, 2001). 
 
          DNA methylation and chromatin structure, or the `tightness' of packaging of the DNA in 
nucleosomes and the higher order structures they form, are physically and functionally linked 
(Bird, 2002). For example, all known catalytically active DNA methyltransferases interact with 
histone deacetylases and the use of inhibitors of each of these processes has revealed that they 
work together to repress transcription (Cameron et al., 1999). Studies in plants, mice, and 
humans, using naturally occurring or engineered mutations in chromatin remodeling machines, 
have indicated that chromatin structure itself may dictate cellular DNA methylation patterns 
(Bird, 2001).  
        Epigenetics is a new frontier in cancer research with tremendous impact on our thinking and 
understanding of biological phenomena and complex diseases, notably cancer. Over the past 
decade there has been remarkable progress in our knowledge of the importance of epigenetic 
events in the control of both normal cellular processes and abnormal events associated with 
tumor development and progression. DNA methylation is a major epigenetic mechanism that is 
most intensively studied in the context of gene regulation and unscheduled silencing in cancer 
cells. Although hypermethylation of gene promoters is in turn associated with gene inactivation, 
the precise consequences of genome-wide hypomethylation are still a matter of discussion. 
Recent studies have helps to explain the mechanisms underlying both promoter-specific 
hypermethylation and global hypomethylation in cancer cells and identified potential targets for 
biomarker discovery and therapeutic intervention. 
       Recent conceptual advances in the field of DNA methylation and the advent and rapid 
development of new technologies in epigenomics have started to solve the mechanisms 
underlying aberrant DNA methylation in cancer cells and identify novel targets for diagnosis, 
risk assessment and therapy. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Literature Review 
Cancer as a genetic and epigenetic disease 
 
The development of cancer is a multistep process. Organisms are maintained by homeostasis, a 
finely tuned balance between cell proliferation and cell death. When the homeostasis is 
disturbed, either by an increased proliferation rate or a decrease in cell death, a neoplasm might 
occur, which can further progress into a tumor. Tumor development is most commonly described 
as natural selection followed by clonal expansion, resulting in monoclonal tumors originating 
from the progeny of a single cell (P.C Nowel,1976). However, cytogenetic studies indicating 
polyclonality have also been reported (S Heim et al). Aberrations that confer growth advantages 
to the cell will accumulate during the clonal selection process. These changes are consequences 
of (1) activation of protooncogenes, rendering the gene constitutively active or active under 
conditions in which the wild type gene is not, (2) inactivation of tumor suppressor genes, 
reducing or abolishing the activity of the gene product, (3) alteration of repair genes, which 
normally keep genetic alterations to a minimum (Vogelstein and Kinzler,2004).     
          
         Genomic analyses focusing on structural and numerical aberrations of chromosomes have 
long suggested that cancer is, in essence, a genetic disease (Vogelstein and Kinzler,2004).The 
first cancer-specific genetic aberration initially identified in 1960 by Nowell and Hungerford and 
was later demonstrated to be the result of a translocation between chromosomes 9 and 22(JD 
Rowley,2001). Today, numerous mutations at the chromosome and DNA level have been 
described in hematological as well as solid tumors (Vogelstein and Kinzler,2004 ;Teixeira , S 
Heim,2005). 
          
          During the last decades, several lines of evidence have proven the importance of 
epigenetic modifications in tumorigenesis. Indeed, epigenetic changes are now recognized to be 
at least as common as genetic changes in cancer (PA Jones and SB Baylin,2002). Moreover, 
epigenetic changes often precede and appear to be essential for several genetic events that drive 
tumor progression. Epigenetic inactivation of key genes in tumorigenesis, like p16INK4a, is seen 
in pre-malignant stages (Belinsky et al,1998)and can allow cells to bypass the cell cycle 
restriction point, setting the stage for accumulation of more aberrations. A more direct link is 
seen with the epigenetic inactivation of the mismatch repair gene MLH1 leading to a 
microsatellite unstable phenotype of genome-wide insertions and deletions typically found in 
short nucleotide repeats (Herman et al, 1998). Such repeats are also present in coding parts of the 
genome and mutations in cancer-critical genes, like TGFBR2, may lead to a selective 
proliferation advantage for the cell (WM Grady, 2004 ;Parsons et al , 1995 ). 
 
Epigenetics 
Conrad Waddington introduced the term “epigenetics” in the 1940s to describe “the interactions 
of genes with their environment, which bring the phenotype into being”( C Waddington, 1942 ). 
Epigenetics literally means “above” the gene. This early usage of the term has been effectively 
displaced during the last decades and today epigenetic inheritance is defined as cellular 
information, other than the DNA sequence itself, that is heritable during cell division (Feinberg, 
B Tycko, 2004). The field of epigenetics has been receiving remarkable attention over recent 
years, indicates that epigenetic inheritance is essential for development and critical cellular 
processes such as gene transcription, differentiation, and protection against viral genomes. 
Epigenetic mechanisms are versatile and adapted for specific cellular memory function not only 
during development but also during life-time. Consistent with the importance of epigenetic 
mechanisms, deregulation of epigenetic states is intimately linked to human diseases, most 
notably cancer. Epigenetic information that fulfils the criterion of heritability can be classified 
into three distinct types: DNA methylation, histone modifications, and non-coding RNAs. 
DNAmethylation refers to a covalent modification of the cytosine base (C) that is located 5’ to a 
guanine base (G) in a CpG dinucleotide . The transfer of methyl groups from S-adenosyl-
methionine (SAM) to cytosine in CpGs is catalysed by several DNA methyltransferases 
(DNMTs). The methylation of DNA has multiple roles in cellular processes, including regulation 
of gene expression (A. Bird , 2002) . Aberrant DNA methylation is universally present in human 
malignancies and is associated with inappropriate gene expression (P.A. Jones, S.B. Baylin , 
2002 ; A.P. Feinberg, B. Tycko , 2004 ; A.P. Feinberg et al , 2006). 
 
  
Fig. 1. Different types of epigenetic information (Carla Sawan et al , 2008). 
 
 
 
 
 
 
DNA Methylation 
DNA methylation is a covalent modification of nucleotides and the most frequently methylated 
nucleotide in the human genome is cytosine subsequently followed by a guanine in the DNA 
sequence, constituting a CpG dinucleotide. The cytosine is methylated in the C-5 position by a 
family of DNA (cytosine-5) methyltransferases (DNMTs) using the universal methyl donor 
Sadenosyl- L-methionine (SAM). 
 
 
 
Fig. 2. Methylation of cytosine within CpG dinucleotides is catalyzed by DNMTs ( Michał W. 
Łuczak and Paweł P. Jagodzinski , 2006). 
 
 
Eukaryotic genomes are not methylated uniformly but contain methylated regions interspersed 
with unmethylated domains (Bird AP , 1986) . During evolution, the dinucleotide CpG has been 
progressively eliminated from the genome of higher eukaryotes and is present at only 5% to 10% 
of its predicted frequency.10-12 Cytosine methylation appears to have played a major role in this 
process, because most CpG sites lost represent the conversion through deamination of 
methylcytosines to thymines. Approximately 70% to 80% of the remaining CpG sites contain 
methylated cytosines in most vertebrates, including humans  (Antequera F, Bird A , 1993 ; Bird 
AP , 1995). These methylated regions are typical of the bulk chromatin that represents the late 
replicating DNA with its attendant histone composition and nucleosomal configuration and is 
relatively inaccessible to transcription factors (Tazi J, Bird A , 1990).  In contrast to the rest of 
the genome, smaller regions of DNA, called CpG islands, ranging from 0.5 to 5 kb and occurring 
on average every 100 kb, have distinctive properties. These regions are unmethylated, GC rich 
(60% to 70%), have a ratio of CpG to GpC of at least 0.6, and thus do not show any suppression 
of the frequency of the dinucleotide CpG (Cross SH, Bird AP , 1995). 
 
CpG Islands 
Methylation of DNA by methyltransferases may occur at any cytosine base converting it to 5’ 
methyl cytosine. It was found that methylation of cytosine bases occur in areas where the bases 
are present proximal to guanine bases so that a CG pair forms. Such pair of dinucleotides are 
called CpG pairs (Watson, 1992).These pairs may occur as isolatedpairs randomly in DNA 
called CpG islands. A CpG island is defined as an area with G+C content greater than 60% and 
the ratio of CpG to GpC of atleast 0.60 (Baylin et al. 1998). Genes that contains CpG islands in 
them are usually housekeeping genes and have a broad pattern of tissue expression. It is found 
that, approximately 2-10% of the human genome consists of CpG islands and that 
approximately70-80% of these CpG islands are in a state of methylation(Antequara et al. 1993 ; 
Bird 1995). 
 
 
 
Fig. 3. Distribution of CpG dinucleotides in human genome. 
DNA Methyltransferases (DNMTs) 
DNA methyltransferases (DNMTs) are the enzymes responsible for both establishing and 
maintaining cellular DNA methylation. Today, three catalytically active DNMTs are known: 
DNMT1, DNMT3A, and DNMT3B. This family of enzyme is divided into maintenance and de 
novo methyltransferases. The enzyme DNMT1 is associated with maintenance methylation and 
hence known as maintenance methyltransferase. Maintenance DNMT1 binds methyl groups to 
the hemimethylated DNA during replication. The enzyme DNMT3A and DNMT3B are 
associated with de novo methylation and hence known as de novo methyltransferase. DNMT3A 
and DNMT3B add methyl groups to CpG dinucleotides of unmethylated DNA. 
 
 
.         
Fig. 4.  Maintenance (A) and de novo DNMTs (B) methylate DNA.  (M. W. Łuczak and P. P. 
Jagodzinski  , 2006)     
 
DNMT1 
The (cytosine-5) DNA methyltransferase 1, referred to as DNMT1 , was the first enzyme to be 
isolated as a mammalian DNA methyltransferase. Generally, DNMTs are believed to be 
composed of two parts, a diversified amino terminal region and a relatively conserved carboxy 
terminal region. DNMT1 has the largest amino terminal region of all the mammalian DNMTs, 
which has roles in regulating the activity of the carboxy terminal catalytic domain, nuclear 
localization, zinc binding, and in mediating protein - protein interactions (Bestor, 2000; 
Robertson, 2001). The carboxy terminal region comprises the catalytic domain that is a common 
feature of all cytosine DNA methyltransferases. DNMT1 has a significant preference for 
hemimethylated double-stranded DNA relative to unmethylated double-stranded DNA.Due to  
this unique property  DNMT1 is commonly referred to as the maintenance methyltransferase 
(Bacolla et al., 1999; Flynn et al., 1996; Glickman et al., 1997; Pradhan et al., 1997, 1999; 
Yokochi and Robertson, 2002). The other isoforms of DNMT1 are DNMT1b , DNMT1o and 
DNMT1p. 
 
DNMT3A 
The human DNMT3A gene was mapped to chromosome 2p23 (Robertson et al., 1999) and 
shows 96% amino acid identity to its murine counter- part (Xie et al., 1999). The carboxy -
terminal portion of DNMT3A includes the catalytic motifs highly conserved in all cytosine DNA 
methyltransferases. DNMT3A has been shown to be enzymatically active both in vitro and in 
vivo by several groups, although these reports differ somewhat in the exact substrate preference 
of DNMT3A (Aoki et al., 2001; Gowher and Jeltsch, 2001; Hsieh, 1999; Lyko et al., 1999; 
Okano et al., 1998a; Yokochi and Robertson, 2002).  
         Proteins of the DNMT3 family commonly have a cysteine-rich domain in the amino 
terminal region, which is referred to as the PHD (plant homeo- domain) region or ATRX-like 
domain , because of its homology with the PHD region of the ATRX gene. ATRX is a member 
of the SNF2/SWI2 family of ATP-dependent chromatin remodeling enzymes. This similarity 
suggests that DNMT3 proteins may be associated with structural changes in chromatin via 
protein - protein interactions at the amino terminal region. DNMT3A transcripts were 
ubiquitously expressed in adult tissues, most tumor cell lines, early embryos, and embryonic 
stem (ES) cells (Okano et al., 1998a; Robertson et al., 1999; Xie et al., 1999). 
 
 
 DNMT3B 
The human DNMT3B gene was mapped to chromosome 20q11.2 (Robertson et al., 1999; Xie et 
al., 1999) and is 85% identical to murine DNMT3B . The catalytic domain, located at the 
carboxy terminus, is well conserved between DNMT3A and DNMT3B (more than 80% 
identity), whereas their amino terminal regions are poorly conserved (less than 30%). DNMT3B, 
like DNMT3A, was shown to be an active DNA methylstransferase in vivo and in vitro (Aoki et 
al., 2001; Hsieh, 1999; Okano et al., 1998a; Qiu et al., 2002).  
           Compared to DNMT3A, the expression levels of DNMT3B are very low in most tissues. 
The testis, however, expressed high levels of DNMT3B, suggesting a crucial function for 
DNMT3B in spermatogenesis (Okano et al., 1998a; Robertson et al., 1999; Xie et al., 1999).  
            In contrast to DNMT3A, there are several isoforms (five for human and eight for mouse) 
of DNMT3B that result from alternative splicing. Three major isoforms, namely DNMT3B1, 
3B2, and 3B3, have been identified  (Okano et al., 1998a), and were shown to be expressed in a 
tissue-specific manner (Robertson et al., 1999). 
 
 
 
Fig. 5. Members of mammalian DNMTs family (Bestor TH (2000) ; Robertson KD et al 1999 ; 
Weisenberger DJ et al , 2004). 
 
 
Table 1. DNA methyltransferase-associated proteins involved in transcriptional repression and 
chromatin modification (KD Robertson , 2002). 
 
Functions of Methylation 
Cytosine methylation has a number of functions. Methylation within gene regulatory elements 
such as promoters, enhancers, insulators, and repressors generally suppresses their function. In 
normal cells, imprinted genes and genes on the inactive X chromosome are the most prominent 
examples of transcriptional repression by methylation. Methylation within gene deficient 
regions, such as in pericentromeric heterochromatin, appears crucial for maintaining the 
conformation and integrity of the chromosome (Ehrlich M , 2000) . Methylation has also been 
proposed as a genome defence against mobile genetic elements (Bestor TH , 1998 ). 
 
 
DNA methylation in transcriptional repression 
 There two mechanisms by which methylation blocks transcription (Nan X et al , 1998 ; Bird AP 
et al , 1999). First, methylation inhibits binding of certain transcription factors to their CpG 
containing recognition sites (Schaffner W et al , 1989 ;  Tate PH, Bird AP , 1999) .A second 
mechanism involves proteins or protein complexes, MeCP2 or MeCP1 respectively, that bind 
specifically to methylated CpGs and can indirectly inhibit the binding of transcription factors by 
reducing access to a regulatory element (Nan X et al, 1998 ; Hendrich B, Bird A , 2000 ; Bird 
AP,Wolffe AP , 1999). 
 
X- chromosome inactivation 
During development, inactivation of one of the two X chromosomes in female cells occurs by a 
process dependent on methylation (Goto T, Monk M , 1998 ). CpG island containing promoters 
of the majority of genes on the inactive X chromosome, including housekeeping genes like 
HPRT, G6PD, and PGK1, are methylated and transcriptionally silent, presumably to ensure 
equivalent expression levels in male and female cells (Kass SU et al , 1997).  For many of these 
genes, silencing precedes methylation (Jaenisch R et al , 1998 ) and may therefore serve to 
maintain silencing, rather than initiating the event. Expression of the XIST (X inactive specific 
transcript) gene is also correlated with methylation status of its promoter, but XIST is 
unmethylated and expressed from the inactive X and methylated and silent on the active X (Goto 
T, Monk M , 1998 ). DNMT1 deleted embryonic stem cells express the normally silenced XIST 
gene on the active X chromosome in males. 
 
Gene imprinting 
Methylation is also important  for the expression of imprinted genes.While the majority of genes 
are expressed from the maternal and the paternal alleles, a small number of “imprinted” genes 
are expressed in a parent of origin specific manner (Tycko B , 1997). Imprinting involves allele 
specific methylation in CpG islands associated with these genes, through mechanisms that are 
not fully understood (Bartolomei MS ,1993; Tremblay KD et al , 1995). 
 
 
DNA methylation and cancer 
 
In comparision to normal cells , the cancer cells show major disruptions in their DNA 
methylation patterns (Baylin SB, Herman JG , 2000). Changes in the overall methylation level 
(global hypomethylation)  and methylation pattern of particular genes (gene specific hypermethylation) 
are characteristic for different types of cancer cells.The influence of DNA methylation on cancer may 
involve the following mechanism: 
                                             (1) Global hypomethylation  
                                             (2) Gene specific hypermethylation 
 
 
 
Fig . 6. Similarities and dissimilarities between DNA hypermethylation and hypomethylation. 
 
DNA hypomethylation 
Hypomethylation  is observed in a wide variety of malignancies (Feinberg AP , Voglstein B, 
1983 ; Kim Yi et al , 1994). It is common in solid tumors such as metastatic hepatocellular 
cancer (Lin CH et al ,2001), in cervical cancer (Kim Yi et al , 1994) , prostate tumors ( Bedford , 
Van Helden PD,1987) ,and also in hematologic malignancies such as B-cell chronic lymphocytic 
leukemia (Ehrlich M, 2002). The global hypomethylation seen in a number of cancers, such as 
breast, cervical, and brain, show a progressive increase with the proficiency of malignancy 
(Ehrlich M, 2002). The pericentric heterochromatin regions on chromosomes 1 and 16 are 
heavily hypomethylated in patients with immunodeficiency, centromeric instability, and facial 
abnormalities and in many cancers. A mutation of DNMT3b has been found in patients with 
immunodeficiency, centromeric instability, and facial abnormalities, which causes the instability 
of the chromatin (Hansen RS et al , 1999 ;Okanom et al ,1999). Hypomethylation causes 
oncogenesis by activation of oncogenes such as cMYC and H-RAS75 or by activation of latent 
retrotransposons (Singer MF et al , 1993 ; Alves G et al , 1996) ,or by chromosome instability 
(Tuck- Muller CM et al .2000). 
 
Chromosome stability 
Chromosome aberrations are common in cancer, and DNA methylation could be involved in the 
control of chromosome stability. It has been shown that patients with the autosomal recessive 
ICF (for immunodeficiency, centromere instability and facial anomalies) syndrome, caused by 
mutation of one of the DNMTs (DNMT3B) (Xu, G.L. et al. (1999)), exhibit demethylation and 
instability of the pericentric heterochromatic regions on chromosomes 1, 9 and 16 (Jeanpierre, 
M. et al. (1993)). Hypomethylation and instability of these regions on chromosomes 1 and 16 
have also been observed in ovarian, breast and Wilms’ tumours (Narayan, A. et al. (1998) ; Qu, 
G.Z. et al. (1999) ; Qu, G. et al. (1999)). However, a clear association between the extent of 
genomic hypomethylation and chromosome instability has yet to be described, and patients with 
ICF syndrome have not been reported to show increases in tumour frequency. 
 
Retrotransposon activation 
 Expression of retrotransposons  is usually suppressed by DNA methylation. However, 
hypomethylation and consequent reactivation of expression from the elements has been detected 
in human cancer (Florl, A.R. et al. (1999)). This could potentially lead to movement of the 
retrotransposons and re-integration at new sites in the genome, leading to insertional 
mutagenesis. However, although mutation due to insertion of mobile genetic elements has been 
observed in cancer (Morse, B. et al. (1988) ; Miki, Y. et al. (1992) ; Bera, T.K. et al. (1998) ), 
such mutations are not frequent, arguing against a major role for such insertional mutagenesis in 
tumour development. 
 
Oncogene activation 
DNA hypomethylation plays an important role in the activation of genes, particularly oncogenes. 
Hypomethylation within the H-ras (Vachtenheim et al , 1994) and c-myc (Cheah, M.S. et al 
,1984) oncogenes has been observed; however, this is not associated with increased expression. 
Several genes mapping to the X-chromosome, in particular the MAGE gene family (De Smet, C. 
et al. (1996)), undergo demethylation within their promoter regions and activation in a tumour-
specific manner. However, no role has been identified for these genes in tumour development.  
 
 
DNA hypermethylation 
Tumor cells exhibit global hypomethylation of the genome accompanied by region-specific 
hypermethylation events (Baylin and Herman, 2000; Jones and Laird, 1999). Most of the 
hypomethylation events appear to occur in repetitive and parasitic elements, which are heavily 
methylated leading to increased transcription from transposable elements and increased genomic 
instability. It has been proposed that the ancestral function of DNA methylation was  to restrain 
the spread of parasitic elements as genomes became larger and more complex and the dangers to 
genome integrity from unrestrained transposition events increased (Bestor and Tycko, 1996; 
Yoder et al., 1997). This genome defense system was then later utilized as a method of gene 
regulation. Regions that are frequent targets of hypermethylation events are CpG islands. CpG 
islands are GpC and CpG-rich regions of approximately 1 kilobase (kb) that are usually 
associated with the promoter or 5'-end of genes . It has been estimated that there are 45 000 CpG 
islands in the human genome and these are associated with roughly half of all genes (Antequera 
and Bird, 1993). CpG island methylation is rare in normal cells. It plays a role in X-chromosome 
inactivation in females and genomic imprinting, increases with age and in vitro cell culture. 
Abnormal methylation of CpG islands can efficiently repress transcription of the associated gene 
in a manner similar  to mutations and deletions and act as one of the `hits' in the Knudsen two-hit 
hypothesis for tumor generation (Baylin and Herman, 2000; Jones and Laird, 1999). There are 
numerous examples of aberrant CpG island promoter hypermethylation of tumor suppressor 
genes, genes involved in cell-cell adhesion, and genes involved with DNA repair . 
 
 
 
Fig. 7. A summary of the most frequent types of sequences affected by cancer-specific DNA 
hypermethylation or hypomethylation. TSG, tumor suppressor genes (Melanie Ehrlich , 2002). 
 
 
 
 
 
 
 
 Fig .8. Model for how global loss and region-specific gain in methylation can occur within the 
same cell and potential contribute to malignant transformation (K D Robertson,2001). 
 
 
 
 
 
Table 2. CpG-island-associated genes involved in cell growth control or metastasis that can 
become hypermethylated and silenced in tumors (K D Robertson. 2001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Objective  
 
As mentioned above that DNMT1, DNMT3a, DNMT3b are overxpressed in many cancers like 
prostate, breast, liver, and colon etc. Deregulation of these genes in human tumors has direct 
oncogenic effects and results essential for cancer cell proliferation. DNA methylation play a role in 
gene silencing by loss of tumor suppression. The expressions of the DNMTs, DNMT1, 
DNMT3A and DNMT3B were examined, since these enzymes have a reported role in the 
maintenance of the genome methylation status integrity and have been implicated in the 
transcriptional regulatory changes of human cancer.  So we have to measure the expression level 
of the particular gene of the enzyme. 
         Our objective of the project is “To compare the expression level of DNMT1, DNMT3a 
and DNMT3b gene  in Normal and various Human Cancer Tissue.” 
 
 
 
 
 
 
 
 
 
 
 
 
 Materials and methods 
The Human blood was collected from CWS Hospital, Rourkela as normal human tissue and Gall 
bladder and Lymph node cancer tissues were collected from Calcutta Medical College, Kolkata. 
Total RNA isolation 
Reagents and Buffers 
• TRIzol Reagents (Sigma), 
• Choloroform, 
• Isopropanol, 
• Ethanol (70%), 
• Denaturation Buffer 
ü 50 % deionized formamide, 
ü 2.2 M formaldehyde, 
ü MOPS buffer (pH 7.0), 
ü 6.6 % glycerol, 
ü 0.5 % bromphenol,  
• Ethidium Bromide (EtBr), 
• Agarose 
 
Protocol 
ü 50-100 mg of tissue in a 2 ml tube with 1 ml TRIzol was transferred. 
ü Homogenized for 60 sec in the polytron. 
ü 200 µl chloroform was added. 
ü It was mixed by inverting the tube for 15 sec. 
ü Incubated for 3 min at room temperature. 
ü Centrifuged at 12.000 g for 15 min. 
ü the aqueous phase was transferred into a fresh Eppendorf tube. 
ü 500 µl isopropanol was added. 
ü Centrifuged at max. 12.000 g for 10 min in the cold room. 
ü The pellet was washed with 500 µl 70 % ethanol. 
ü Centrifuged at max. 7.500 g for 5 min in the cold room. 
ü The pellet was dried on air for 10 min. 
ü Then the pellet was dissolved in 50-100 µl DEPC-H2O. 
ü Incubated for 10 min at 60° C. 
ü Spectrophotometric reading was taken. 
ü Analysed the RNA on a MOPS gel: 
Ø 1-3 µg RNA was dissolved in 11 µl denaturation buffer. 
Ø 1 µl Ethidium bromide (1mg/ml) was added and denatured at 65° C for 15 min 
Ø 1 % agarose gel was loaded in MOPS buffer plus 5 % formaldehyde. 
Ø The gel was run at 40 V for 4 h. 
 
 cDNA synthesis (RT -PCR) 
Regents and Buffer 
• 5X First Strand Buffer 
• 10mM dNTP Set 
• 0.1M DTT 
• Random Primers 
• RNase OUT Ribonuclease Inhibitor 
• Super Script II RNase H- Reverse Transcriptase 
 
 
Protocol 
ü 8µl of total RNA were taken. 
ü Then 3 µl Random Primers was added. 
ü 1 µl dNTP mix was added. 
ü Then vortex and spin downed tube. 
ü Incubated at 65°C for 5 min. 
ü Placed tube on ice. 
ü 4 µl 5X Buffer, 2 µl DTT and 1µl RNAseOut were added. 
ü Then vortex and spin downed tube. 
ü Incubated at 42°C for 1 min. 
ü 1µl SuperScript II RNase H- Reverse Transcriptase was added. 
ü Incubated at 42°C for 60 min. 
ü Incubated at 70°C for 15 min. 
ü 180 µl of molecular grade water was added. 
ü Nanodrop 1000 was used to measure concentration. Set sample typesetting to Other 
Sample and the constant to 33. 
ü Stored at -80°C. 
 
Gene specific PCR 
Used Primers 
 
Gene Name Sense Primer Antisense Primer 
DNMT1 ACCAAGCAAGAAGTGAAGCC GCTTCCTGCAGAAGAACCTG 
DNMT3A CACACAGAAGCATATCCAGGAGTG AGTGGACTGGGAAACCAAATACCC 
DNMT3B AATGTGAATCCAGCCAGCCAGGAAAGGC ACTGGATTACACTCCAGGAACCGT 
β-Actin TCTACAATGAGCTGCGTGTG ATCTCCTTCTGCATCCTGTC 
                                                                                         
                                                                                                       (Patra et.al, 2002) 
 
 
 PCR Condition (for β-actin gene) 
1. Initial denaturation-94°C /1 min for 30 cycle 
2. Denaturation-94°C /20 sec for 30 cycle 
3. Annealing-57°C /20sec  for 30 cycle 
4. Elongation-72°C/30sec  
5. Final Elongation-72°C/5min 
 
94oC1:00[94o C0:20; 58˚C0:20; 72oC 0.30]30; 72oC 5:00   (for DNMT1). 
94oC1:00[94o C0:20; 65˚C0:20; 72oC 0.30]30; 72oC 5:00   (for DNMT3A) 
94oC1:00[94o C0:20; 57˚C0:20; 72oC 0.30]30; 72oC 5:00  ( for DNMT3B) 
 
PCR Mix  
dNTP- 5.5µl 
Mgcl2-16.5µl 
PCR buffer-27.5µl 
Template-22µl 
Taq polymerase-5.5µl 
Water-192.5µl 
 
 
Results and discussions 
From Normal Tissue (Blood) 
Product Concn. (µg/ml) Purity 
260/280 260/230 
Total RNA 570.32 1.34 0.82 
   Table.3 Spectrophotometer results of total RNA from blood tissue 
 
 
 
 
 
 
 
 
Gene Concn. (µg/ml) Purity 
260/280 260/230 
DNMT1 263.25 1.71 1.03 
DNMT3A 286.69 1.79 0.96 
DNMT3B 301.58 1.83 0.89 
   Table.4.  Spectrophotometer results of gene specific amplification product from blood 
 
 
(Fig. 10 .Total RNA in denaturation gel) 
(Fig.9. Total RNA in 1% agarose 
gel) 
From Cancerous Tissue 
Tissue Concn. (µg/ml) Purity 
260/280 260/230 
Gall Bladder Cancer 234.67 1.03 0.65 
Lymph Node Cancer 478.51 1.61 1.02 
  Table.5 . Spectrophotometer results of total RNA from cancer tissue 
 
                                            Lane.1, 2, 3, 4: Lymph Node Cancer 
  
 
 
Gene Concn. (µg/ml) Purity 
260/280 260/230 
DNMT1 168.23 1.74 1.28 
DNMT3A 312.78 1.87 1.31 
DNMT3B 353.69 1.69 1.25 
 Table.6 .Spectrophotometer results of gene specific amplification product from lymph node            
cancer tissue  
 
 
1    2   3    4 
(Fig . 12.Total RNA in denaturation gel) 
  
                                                     Lane.1: β-actin 
                                                                  Lane.3: DNMT1 
                                                                   Lane.7: 1kb Ladder   
 
 
(Fig . 13.Gene specific PCR amplification) 
 
 
 
 
                                                  
                                                            Lane1: β-actin 
Lane 2: DNMT3a 
Lane 3: DNMT3b 
Lane 4: 1 kb Ladder 
                                                                                        
                                  (Fig . 14. Gene specific PCR amplification) 
 
 
 
1   2       3     4    5    6    7     8 
1      2       3      4    5     6     7    8 
After isolation the total RNA from normal blood and Cancerous tissue, we checked their 
concentration by taking its OD in spectrophotometer, in case of Gall Bladder the concentration 
was found to be very low i.e. 234.67µg/ml, which was very low compare to the other samples 
reading. Because it was took a lot of time to processing after collecting the sample and also 
cDNA was not synthesize from the total RNA by RT-PCR method due to some unfavourable 
condition. 
It was observed, after gene specific amplification , the concentration of DNMT3A and DNMT3B 
were i.e. 286.69 and 301.58 respectively in normal blood cells, but in cancerous tissue the 
concentration were found to increase i.e. 312.78 and 353.69 respectively.  
 
 
 
 
 
 
 
 
 
 
 
 
Conclusion 
As indicated by the above results DNMTs are seen to over express in Lymph Node cancer tissue. 
So from this it was concluded that these over expression of DNMTs leads to hypermethylation of 
tumor suppressor genes which in turn decrease the expression of tumor suppressor genes  and 
cause  cancer. 
          It was still unclear from the above studies that, whether DNMTs are cause of methylation 
of promoter region of tumor suppressor genes which cause their gene silencing and tumor 
formation. 
          The role of DNMTs in causing cancer can be further confirmed by carrying out Real-Time 
PCR, which gives accurate quantitative estimation of mRNA and further bisulphite modification 
and methylation specific-PCR (MSP), which can help to locate the exact methylation site at the 
tumor suppressor genes  whether it is on promoter region or not. 
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